SCYX Short Interest Plunges 87.6% as ENSC Spikes 619.9%

For biotech investors, short interest is a conviction signal as much as a derivative metric. SCYNEXIS's 87.6% collapse in short interest suggests bearish positions are being unwound, potentially ahead of clinical or financing catalysts, while Ensysce's 619.9% spike reveals accelerating distress. Understanding which microcap biotechs are being abandoned by shorts—and which are being targeted—can flag both turnarounds and dilution risk.

The June 15 short interest settlement date delivered a stark divergence across three Nasdaq-listed microcap healthcare-related equities. SCYNEXIS, Inc. (NASDAQ: SCYX) saw short interest collapse from 2,578,236 shares on May 31 to 320,181 shares, an 87.6% decline. At the same time, Ensysce Biosciences, Inc. (NASDAQ: ENSC) experienced a 619.9% surge in short interest, from 50,601 shares to 364,278, while Focus Universal, Inc. (NASDAQ: FCUV) saw shorts increase 282.8%, from 13,849 to 53,009. These figures are not merely statistical noise; they reveal sharply different expectations about the near-term viability and share-price direction of three small companies operating at the fragile end of the healthcare and biotech spectrum.

“

The stock traded at $0.30 on Friday, with a market capitalization of just $4.62 million and a 52-week range of $0.23 to $2.75.

SCYNEXIS, an antifungal-focused biopharmaceutical company, appears to have experienced a meaningful short-covering event. With only 320,181 shares sold short, representing roughly 3.4% of the float, and a days-to-cover ratio of 5.0 based on average daily volume of just 64,478 shares, the remaining bearish position is still notable given the stock's thin liquidity. Institutional ownership stands at 54.37%, with several funds adding positions during recent quarters, though the dollar amounts involved are tiny by institutional standards. Jane Street Group's new $27,000 position, GSA Capital's $80,000 stake, Renaissance Technologies' $206,000 holding, Bridgeway Capital's $248,000 position, and Geode Capital's $284,000 stake all suggest passive index replication or quant-driven exposure rather than high-conviction bets. The sharp decline in short interest could indicate that bears are covering ahead of potential catalysts, but the lack of a visible upgrade cycle is a counterweight: Wall Street Zen downgraded SCYNEXIS from buy to sell on the same publication date, suggesting that at least one research provider sees further downside risk despite the short covering.

Ensysce Biosciences presents a far more distressed picture. Short interest surged 619.9% to 364,278 shares, but because average daily trading volume is 1,391,722 shares, the days-to-cover ratio is only 0.3, meaning shorts could exit their entire position in less than a day if needed. The stock traded at $0.30 on Friday, with a market capitalization of just $4.62 million and a 52-week range of $0.23 to $2.75. Institutional ownership is only 5.63%, with hedge fund positions such as Virtu Financial's $34,000 stake, Citadel Advisors' $34,000 position, Adage Capital's $138,000 holding, and DRW Securities' $91,000 stake, again reflecting small, likely programmatic exposure. A 619.9% jump in short interest from a low base of just over 50,000 shares can be amplified by algorithmic trading and convertible-arbitrage hedging, but the overall trajectory is unmistakably bearish for a company trading near its 52-week low with negative earnings.

Focus Universal, a developer of smart instrumentation platforms and wireless sensor devices, is the most heavily shorted of the three as a percentage of float, with 9.8% of shares sold short despite the relatively modest absolute total of 53,009 shares. The stock fell $0.39 on Friday to $4.37, against a 200-day moving average of $25.41 and a 52-week high of $210.00, underscoring a severe long-term downtrend. The company's market cap has dwindled to $3.07 million, and its most recent quarterly report showed just $0.05 million in revenue against analyst expectations of $0.40 million, a negative net margin of 4,243.03%, and a negative return on equity of 357.95%. Weiss Ratings reissued a sell rating on FCUV the same week, aligning with the MarketBeat consensus of sell. The 282.8% rise in short interest from an extremely low prior level reflects growing conviction that Focus Universal's cash position and commercial trajectory are unsustainable.